| Effective immunotherapy of weakly immunogenic solid tumours using a combined immunogene therapy and regulatory T-cell inactivation. | |
| | |
MedLine Citation:
|
PMID: 20186173 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Obstacles to effective immunotherapeutic anti-cancer approaches include poor immunogenicity of the tumour cells and the presence of tolerogenic mechanisms in the tumour microenvironment. We report an effective immune-based treatment of weakly immunogenic, growing solid tumours using a locally delivered immunogene therapy to promote development of immune effector responses in the tumour microenvironment and a systemic based T regulatory cell (Treg) inactivation strategy to potentiate these responses by elimination of tolerogenic or immune suppressor influences. As the JBS fibrosarcoma is weakly immunogenic and accumulates Treg in its microenvironment with progressive growth, we used this tumour model to test our combined immunotherapies. Plasmids encoding GM-CSF and B7-1 were electrically delivered into 100 mm(3) tumours; Treg inactivation was accomplished by systemic administration of anti-CD25 antibody (Ab). Using this approach, we found that complete elimination of tumours was achieved at a level of 60% by immunogene therapy, 25% for Treg inactivation and 90% for combined therapies. Moreover, we found that these responses were immune transferable, systemic, tumour specific and durable. Combined gene-based immune effector therapy and Treg inactivation represents an effective treatment for weakly antigenic solid growing tumours and that could be considered for clinical development. |
| | |
Authors:
|
M C Whelan; G Casey; M MacConmara; J A Lederer; D Soden; J K Collins; M Tangney; G C O'Sullivan |
Related Documents
:
|
1180973 - Role of macrophages in immunity, with special reference to tumour immunology. a review. 18553083 - Inhibition of activation of dsrna-dependent protein kinase and tumour growth inhibition. 8565523 - Toward a theory regarding the pathogenesis of the systemic inflammatory response syndro... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-02-26 |
Journal Detail:
|
Title: Cancer gene therapy Volume: 17 ISSN: 1476-5500 ISO Abbreviation: Cancer Gene Ther. Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-06-17 Completed Date: 2010-10-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9432230 Medline TA: Cancer Gene Ther Country: England |
Other Details:
|
Languages: eng Pagination: 501-11 Citation Subset: IM |
Affiliation:
|
Cork Cancer Research Centre, Mercy University Hospital and Leslie C Quick Jnr Laboratory, University College Cork, Cork, Ireland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antigen Presentation Antigens, CD80 / genetics Cell Line, Tumor Combined Modality Therapy Fibrosarcoma / genetics, immunology, therapy* Gene Therapy / methods* Granulocyte-Macrophage Colony-Stimulating Factor / genetics Humans Immunogenetic Phenomena Immunotherapy / methods* Interleukin-2 Receptor alpha Subunit / immunology Mice Mice, Inbred BALB C Neoplasms / genetics, immunology, therapy* T-Lymphocytes, Regulatory / immunology* |
| Chemical | |
Reg. No./Substance:
|
0/Antigens, CD80; 0/Interleukin-2 Receptor alpha Subunit; 83869-56-1/Granulocyte-Macrophage Colony-Stimulating Factor |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Enhanced anti-tumor effects of combined MDR1 RNA interference and human sodium/iodide symporter (NIS...
Next Document: The Kidney Early Evaluation Program (KEEP) of Japan: results from the initial screening period.